ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sanofi Buys Into Heart Therapy Programs

by Rick Mullin
September 22, 2014 | APPEARED IN VOLUME 92, ISSUE 38

Sanofi and MyoKardia have entered a drug development partnership targeting therapies for genetic heart disease. The deal includes three MyoKardia programs, two focused on hypertrophic cardiomyopathy and one on dilated cardiomyopathy. MyoKardia has received $45 million, including up-front licensing fees and an undisclosed equity investment. The firm may receive up to a total of $200 million in milestone payments and equity investment. Under the partnership, MyoKardia will manage research and development through early human efficacy studies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment